Comparative Pharmacology
Head-to-head clinical analysis: BROMANATE DM versus PHERAZINE VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMANATE DM versus PHERAZINE VC.
BROMANATE DM vs PHERAZINE VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist; it also inhibits serotonin reuptake and acts on the cough center. Brompheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; chlorpheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors; promethazine is a phenothiazine derivative with antihistamine, sedative, antiemetic, and anticholinergic effects.
2.5 mg orally three times daily (every 8 hours); maximum 10 mg in 24 hours.
10 mg orally every 6 hours as needed; maximum 60 mg per day.
None Documented
None Documented
Brompheniramine: 24.9 ± 9.3 hours. Dextromethorphan: 3-4 hours for extensive metabolizers (CYP2D6); 24-48 hours for poor metabolizers. Clinical context: Steady state reached in ~5 days for brompheniramine; accumulation in poor metabolizers may require dose adjustment.
Terminal elimination half-life is approximately 9-16 hours; clinical context: steady-state achieved in 2-3 days.
Brompheniramine is primarily excreted via renal elimination (approximately 70-85% as metabolites and unchanged drug). Dextromethorphan and its metabolites are excreted renally (about 60% as unchanged dextromethorphan and dextrorphan glucuronide conjugates). Biliary/fecal excretion accounts for the remainder.
Primarily renal as metabolites and unchanged drug; about 70% excreted in urine, 20% in feces via biliary elimination.
Category C
Category C
Cough and Cold Combination
Cough and Cold Combination